Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 neoadjuvant nivolumab in MSI-H/dMMR locally advanced colorectal cancer
jRCTs031230018Phase 2Suspended
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in colorectal adenocarcinoma. Primary endpoint: Overall response rate. Started Apr 2023; status: suspended.
02
Drugs
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on jRCTs031230018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230018.